We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Proton MR Spectroscopy of Brain Metastases in Evaluation of Treatment Response.

This study has been withdrawn prior to enrollment.
(no patients recruited)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00184288
First Posted: September 16, 2005
Last Update Posted: November 2, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
The Royal Norwegian Ministry of Health
Information provided by (Responsible Party):
Norwegian University of Science and Technology
  Purpose
The aim of the study is to investigate the feasibility of in vivo single volume MR spectroscopy in evaluation of treatment response in patients with brain metastases, using 3T MR instrument. In order to optimize and avoid ineffective treatment of patients with brain metastases, in vivo MR spectroscopy can be an useful tool.

Condition
Neoplasm Metastasis Lung Neoplasms Breast Neoplasms Melanoma

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Single Volume 1H MR Spectroscopy of Brain Metastases in Evaluation of Treatment Response.

Resource links provided by NLM:


Further study details as provided by Norwegian University of Science and Technology:

Enrollment: 0
Study Start Date: November 2004
Study Completion Date: December 2010
Primary Completion Date: June 2006 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients with brain metastases
Criteria

Inclusion Criteria:

  • Clinical diagnosis of brain metastases

Exclusion Criteria:

  • children
  • pregnancy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00184288


Locations
Norway
Norwegian University of Science and Technology, Faculty of Medicine
Trondheim, Norway, N-7489
Sponsors and Collaborators
Norwegian University of Science and Technology
The Royal Norwegian Ministry of Health
Investigators
Study Director: Steinar Lundgren, MD PhD Cancer clinic, St.Olavs Hospital Trondheim University Hospital
  More Information

Responsible Party: Norwegian University of Science and Technology
ClinicalTrials.gov Identifier: NCT00184288     History of Changes
Other Study ID Numbers: 11184
First Submitted: September 13, 2005
First Posted: September 16, 2005
Last Update Posted: November 2, 2011
Last Verified: October 2011

Keywords provided by Norwegian University of Science and Technology:
Lipid
choline
metastasis
magnetic resonance spectroscopy
treatment response

Additional relevant MeSH terms:
Neoplasms
Neoplasm Metastasis
Neoplasms, Second Primary
Breast Neoplasms
Lung Neoplasms
Neoplastic Processes
Pathologic Processes
Neoplasms by Site
Breast Diseases
Skin Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Lung Diseases
Respiratory Tract Diseases